Evonile Pharma (EVONILE) Q2 FY27 Posts ₹78 Crore Q2 Loss as Business Model Reset Bites
The pharmaceutical company swung to a deep quarterly loss as it booked heavy one-time costs to end a single-customer model and build its own distribution network.
Evonile Pharma reported a net loss of ₹78 crore for Q2 FY27, a sharp reversal from a ₹24 crore profit a year ago. Revenue fell 38% as the company severed ties with a major customer and invested heavily in its own commercial infrastructure.
Evonile Pharma’s first quarter under new ownership was a deliberate reset, not an operational failure. The company is dismantling its old, dependent commercial model to build an independent pharmaceutical platform, and the September quarter bore the full brunt of that costly transition.
The numbers show a business in the middle of a painful pivot. Revenue collapsed to ₹56 crore, down 38% from a year ago and 46% from the prior quarter. The company swung to a net loss of ₹78 crore from a ₹24 crore profit last year. This stark reversal is captured in the recent trend.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 56.0YoY -38% | 103.8 | 90.3 |
| Profit (₹ Cr) | -78.0YoY -422% | 32.2 | 24.2 |
The ₹83 Crore Reset Bill
Management, in a call covered by Investing.com, was clear that the quarter’s plunge was mechanical. It resulted from ending a relationship with a single large customer that accounted for ₹41 crore of sales in Q2 last year. The cost of that break was severe: ₹83 crore in one-time charges. This included a ₹68 crore exceptional item, largely for terminating promotion rights and inventory arrangements, and ₹15 crore for transition and acquisition costs.
These charges explain the surge in total expenses and the negative other income line. They also drove a massive year-on-year increase in reported interest and depreciation, linked to financing and amortizing newly acquired brands like Minipress XL.
Building the Machine Ahead of Sales
While revenue fell, operating costs for the new business were ramping up. Employee expenses soared 171% to ₹14.4 crore, as the company builds a 900-person field force. According to the company’s presentation, this sales team should be complete by the end of Q3 or early Q4 FY27. The strategy is to invest in distribution and promotion now, hoping to unlock growth from its portfolio of leading brands later.
The balance sheet shifted dramatically to fund this ambition. To acquire the Minipress XL brand, Evonile took on ₹800 crore in new debt, pushing total borrowings to ₹796 crore by September. A report from Multibagg.ai noted that operating cash flow remained strong at ₹138 crore for the half-year, providing liquidity during the build-out.
A Timeline for Stability
Guidance from management sets clear milestones for the transition’s end. The Investing.com transcript notes another ₹15-20 crore in one-time costs are expected in Q3 FY27. The company targets stabilization by Q4 FY27 or Q1 FY28, when the “actual cost structure” will be visible.
Once stable, management sees a base of around ₹600 crore in annualized revenue. Their ambition is to double that organically over five to six years, targeting growth above the broader pharmaceutical market. New product launches are slated to begin in late Q4 FY27 or Q1 FY28.
Key Points
- Evonile Pharma’s Q2 FY27 loss of ₹78 crore was primarily driven by ₹83 crore in one-time transition costs as it ended a major customer relationship.
- Revenue fell 38% YoY due to the loss of ₹41 crore in sales from that customer, partly offset by ₹7 crore from the new in-house division.
- The company is aggressively building its own commercial platform, with employee costs up 171% and total debt at ₹796 crore to fund brand acquisitions.
- Management expects operations to stabilize by Q4 FY27 or Q1 FY28, targeting a ₹600 crore revenue base and above-market organic growth thereafter.
Hexa Perspective
This quarter is a line in the sand between Evonile’s past as a subsidiary and its future as an independent company. The reported loss, while severe, is largely a capitalized investment in a direct sales and distribution network. The real test begins now.
Investors are effectively funding a startup built on legacy brands. The next two quarters will reveal if the new commercial machine can recapture lost sales and grow the portfolio. Success hinges on the field force achieving targeted productivity before the high fixed-cost structure and debt load pressure margins further. The promise is a more valuable, self-reliant company; the risk is that the transition proves longer and more expensive than planned.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
